Who’s Hired? Makov To Step Away From Sun Pharma After 10 Years
Updates Also Announced By Mayne, Avet, Amneal And AAM
While Israel Makov steps away from Sun Pharmaceuticals, Mayne and Avet bring in new executives, Amneal appoints a new director and the AAM promotes a loyal colleague.
You may also be interested in...
Looking back over the third quarter of 2022, Generics Bulletin executive editor Dave Wallace picks out highlights from July to September that include changes in ownership on the horizon for major industry players, executive reshuffles at the top of leading companies and regulators, Generics Bulletin’s annual Top 50 and the announcement of our annual awards shortlist.
Summer’s end brings notable leadership reshuffles across four continents and five companies. Stada has appointed its head of mid-sized European markets as its UK lead while Gustavo Pesquin joins Amneal from Sanofi.
Tildrakizumab, including Ilumetri end market numbers, nears $500m sales mark, with the contribution of Sun's wider specialty business nearly doubling since fiscal 2018. The anti-IL-23p19 monoclonal antibody has seen global sales spurt 81% in fiscal 2022, while acne therapy Winlevi has been well received by dermatologists in the US.